Harnessing the immune response against cancer

Harnessing the immune response against cancer. We have shown that tumour-specific CD4+ T cells, with a Th2 cytokine profile, are extremely effective at eliminating tumours by recruiting tumouricidal eosinophils into tumours. Eosinophils also play a critical role in tumour immunosurveillance. How eosinophils eliminate tumours and whether adaptive immunity is essential for eosinophil activation are areas of current research. In collaboration with Dr Joe Altin (Research School of Biology, ANU) we have also developed a liposome-based vaccine against cancer that targets dendritic cells. Research is continuing, in collaboration with the start-up biotechnology company Lipotek, to develop better liposome-based vaccines against cancer and other diseases.

Updated:  22 September 2017/Responsible Officer:  Director, JCSMR/Page Contact:  Web Manager